Previous Article | Next Article 
Journal of Virology, May 2000, p. 4562-4569, Vol. 74, No. 10
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Multiple Antiviral Activities of Cyanovirin-N: Blocking of Human
Immunodeficiency Virus Type 1 gp120 Interaction with CD4 and Coreceptor
and Inhibition of Diverse Enveloped Viruses
Barna
Dey,1
Danica L.
Lerner,2
Paolo
Lusso,3
Michael R.
Boyd,4
John H.
Elder,2 and
Edward A.
Berger1,*
Laboratory of Viral Diseases, National Institute of Allergy
and Infectious Diseases, National Institutes of Health, Bethesda,
Maryland 20892-04451; Department of
Molecular Biology, The Scripps Research Institute, La Jolla, California
920372; Unit of Human Virology,
Department of Biological and Technological Research, San Raffaele
Scientific Institute, 20132 Milan, Italy3;
and Laboratory of Drug Discovery Research and Development,
Developmental Therapeutics Program, Division of Cancer Treatment
and Diagnosis, National Cancer Institute, Frederick Cancer Research
and Development Center, Frederick, Maryland
217024
Received 14 September 1999/Accepted 16 February 2000
Cyanovirin-N (CV-N) is a cyanobacterial protein with potent
neutralizing activity against human immunodeficiency virus (HIV). CV-N
has been shown to bind HIV type 1 (HIV-1) gp120 with high affinity;
moreover, it blocks the envelope glycoprotein-mediated membrane fusion reaction associated with HIV-1 entry. However, the
inhibitory mechanism(s) remains unclear. In this study, we show that
CV-N blocked binding of gp120 to cell-associated CD4. Consistent with
this, pretreatment of gp120 with CV-N inhibited soluble CD4
(sCD4)-dependent binding of gp120 to cell-associated CCR5. To
investigate possible effects of CV-N at post-CD4 binding steps,
we used an assay that measures sCD4 activation of the HIV-1 envelope
glycoprotein for fusion with CCR5-expressing cells.
CV-N displayed equivalently potent inhibitory effects when added before or after sCD4 activation, suggesting that CV-N also has blocking action
at the level of gp120 interaction with coreceptor. This effect was
shown not to be due to CV-N-induced coreceptor down-modulation after
the CD4 binding step. The multiple activities against the HIV-1
envelope glycoprotein prompted us to examine other
enveloped viruses. CV-N potently blocked infection by feline
immunodeficiency virus, which utilizes the chemokine receptor CXCR4 as
an entry receptor but is CD4 independent. CV-N also inhibited fusion
and/or infection by human herpesvirus 6 and measles virus but not by vaccinia virus. Thus, CV-N has broad-spectrum antiviral activity, both
for multiple steps in the HIV entry mechanism and for diverse enveloped
viruses. This broad specificity has implications for potential clinical
utility of CV-N.
*
Corresponding author. Mailing address: Laboratory of
Viral Diseases, National Institute of Allergy and Infectious Diseases, Building 4, room 237, National Institutes of Health, Bethesda, MD
20892. Phone: (301) 402-2481. Fax: (301) 480-1147. E-mail: edward_berger{at}nih.gov.
Journal of Virology, May 2000, p. 4562-4569, Vol. 74, No. 10
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Zhou, J., Swiderski, P., Li, H., Zhang, J., Neff, C. P., Akkina, R., Rossi, J. J.
(2009). Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res
37: 3094-3109
[Abstract]
[Full Text]
-
Hori, K., Sato, Y., Ito, K., Fujiwara, Y., Iwamoto, Y., Makino, H., Kawakubo, A.
(2007). Strict specificity for high-mannose type N-glycans and primary structure of a red alga Eucheuma serra lectin. Glycobiology
17: 479-491
[Abstract]
[Full Text]
-
Barrientos, L. G., Matei, E., Lasala, F., Delgado, R., Gronenborn, A. M.
(2006). Dissecting carbohydrate-Cyanovirin-N binding by structure-guided mutagenesis: functional implications for viral entry inhibition. Protein Eng Des Sel
19: 525-535
[Abstract]
[Full Text]
-
Liu, X., Lagenaur, L. A., Simpson, D. A., Essenmacher, K. P., Frazier-Parker, C. L., Liu, Y., Tsai, D., Rao, S. S., Hamer, D. H., Parks, T. P., Lee, P. P., Xu, Q.
(2006). Engineered vaginal lactobacillus strain for mucosal delivery of the human immunodeficiency virus inhibitor cyanovirin-N.. Antimicrob. Agents Chemother.
50: 3250-3259
[Abstract]
[Full Text]
-
Pashov, A., MacLeod, S., Saha, R., Perry, M., VanCott, T. C., Kieber-Emmons, T.
(2005). Concanavalin A binding to HIV envelope protein is less sensitive to mutations in glycosylation sites than monoclonal antibody 2G12. Glycobiology
15: 994-1001
[Abstract]
[Full Text]
-
Moore, J. P., Shattock, R. J.
(2003). Preventing HIV-1 sexual transmission--not sexy enough science, or no benefit to the bottom line?. J Antimicrob Chemother
52: 890-892
[Full Text]
-
Vermeire, K., Schols, D.
(2003). Specific CD4 down-modulating compounds with potent anti-HIV activity. J. Leukoc. Biol.
74: 667-675
[Abstract]
[Full Text]
-
O'Keefe, B. R., Smee, D. F., Turpin, J. A., Saucedo, C. J., Gustafson, K. R., Mori, T., Blakeslee, D., Buckheit, R., Boyd, M. R.
(2003). Potent Anti-Influenza Activity of Cyanovirin-N and Interactions with Viral Hemagglutinin. Antimicrob. Agents Chemother.
47: 2518-2525
[Abstract]
[Full Text]
-
Hong, P. W.-P., Flummerfelt, K. B., de Parseval, A., Gurney, K., Elder, J. H., Lee, B.
(2002). Human Immunodeficiency Virus Envelope (gp120) Binding to DC-SIGN and Primary Dendritic Cells Is Carbohydrate Dependent but Does Not Involve 2G12 or Cyanovirin Binding Sites: Implications for Structural Analyses of gp120-DC-SIGN Binding. J. Virol.
76: 12855-12865
[Abstract]
[Full Text]
-
Botos, I., O'Keefe, B. R., Shenoy, S. R., Cartner, L. K., Ratner, D. M., Seeberger, P. H., Boyd, M. R., Wlodawer, A.
(2002). Structures of the Complexes of a Potent Anti-HIV Protein Cyanovirin-N and High Mannose Oligosaccharides. J. Biol. Chem.
277: 34336-34342
[Abstract]
[Full Text]
-
Sanders, R. W., Venturi, M., Schiffner, L., Kalyanaraman, R., Katinger, H., Lloyd, K. O., Kwong, P. D., Moore, J. P.
(2002). The Mannose-Dependent Epitope for Neutralizing Antibody 2G12 on Human Immunodeficiency Virus Type 1 Glycoprotein gp120. J. Virol.
76: 7293-7305
[Abstract]
[Full Text]
-
Beutler, J. A., McMahon, J. B., Johnson, T. R., O'Keefe, B. R., Buzzell, R. A., Robbins, D., Gardella, R., Wilson, J., Boyd, M. R.
(2002). High Throughput Screening for Cyanovirin-N Mimetics Binding to HIV-1 gp4l. J Biomol Screen
7: 105-110
[Abstract]
-
Bolmstedt, A. J., O'Keefe, B. R., Shenoy, S. R., McMahon, J. B., Boyd, M. R.
(2001). Cyanovirin-N Defines a New Class of Antiviral Agent Targeting N-Linked, High-Mannose Glycans in an Oligosaccharide-Specific Manner. Mol. Pharmacol.
59: 949-954
[Abstract]
[Full Text]
-
Shenoy, S. R., O'Keefe, B. R., Bolmstedt, A. J., Cartner, L. K., Boyd, M. R.
(2001). Selective Interactions of the Human Immunodeficiency Virus-Inactivating Protein Cyanovirin-N with High-Mannose Oligosaccharides on gp120 and Other Glycoproteins. J. Pharmacol. Exp. Ther.
297: 704-710
[Abstract]
[Full Text]
-
Mori, T., Boyd, M. R.
(2001). Cyanovirin-N, a Potent Human Immunodeficiency Virus-Inactivating Protein, Blocks both CD4-Dependent and CD4-Independent Binding of Soluble gp120 (sgp120) to Target Cells, Inhibits sCD4-Induced Binding of sgp120 to Cell-Associated CXCR4, and Dissociates Bound sgp120 from Target Cells. Antimicrob. Agents Chemother.
45: 664-672
[Abstract]
[Full Text]
-
O'Keefe, B. R., Shenoy, S. R., Xie, D., Zhang, W., Muschik, J. M., Currens, M. J., Chaiken, I., Boyd, M. R.
(2000). Analysis of the Interaction between the HIV-Inactivating Protein Cyanovirin-N and Soluble Forms of the Envelope Glycoproteins gp120 and gp41. Mol. Pharmacol.
58: 982-992
[Abstract]
[Full Text]
-
D'Souza, M. P., Cairns, J. S., Plaeger, S. F.
(2000). Current Evidence and Future Directions for Targeting HIV Entry: Therapeutic and Prophylactic Strategies. JAMA
284: 215-222
[Abstract]
[Full Text]